Acquisition by Cockroft Bettina M of 8300 shares of Cns Pharmaceuticals subject to Rule 16b-3
| CNSP Stock | USD 0.11 0.01 11.00% |
Slightly above 51% of Cns Pharmaceuticals' retail investors are presently thinking to get in. The analysis of overall sentiment of trading Cns Pharmaceuticals stock suggests that some investors are interested at this time. Cns Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Cns Pharmaceuticals. Many technical investors use Cns Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Cns |
Filed transaction by Cns Pharmaceuticals Inc director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
Cns Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Cns Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Cns Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Cns Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cns Pharmaceuticals Fundamental Analysis
We analyze Cns Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cns Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cns Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Cns Pharmaceuticals is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Cns Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cns Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Cns Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cns Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Cns Pharmaceuticals Related Equities
| TEVA | Teva Pharma | 25.38 | ||||
| HLN | Haleon Plc | 1.74 | ||||
| NBIX | Neurocrine Biosciences | 1.27 | ||||
| AMPH | Amphastar | 1.20 | ||||
| ALVO | Alvotech | 0.17 | ||||
| EBS | Emergent Biosolutions | 1.35 |
Additional Tools for Cns Stock Analysis
When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.